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Abstract
Ad[I/PPT-E1A] is an oncolytic adenovirus that specifically kills prostate cells via restricted replication by a
prostate-specific regulatory element. Off-target replication of oncolytic adenoviruses would have serious clinical
consequences. As a proposed ex vivo test, we describe the assessment of the specificity of Ad[I/PPT-E1A] viral
cytotoxicity and replication in human nonprostate primary cells. Four primary nonprostate cell types were selected
to mimic the effects of potential in vivo exposure to Ad[I/PPT-E1A] virus: bronchial epithelial cells, urothelial cells,
vascular endothelial cells, and hepatocytes. Primary cells were analyzed for Ad[I/PPT-E1A] viral cytotoxicity in
MTS assays, and viral replication was determined by hexon titer immunostaining assays to quantify viral hexon
protein. The results revealed that at an extreme multiplicity of infection of 500, unlikely to be achieved in vivo,
Ad[I/PPT-E1A] virus showed no significant cytotoxic effects in the nonprostate primary cell types apart from the
hepatocytes. Transmission electron microscopy studies revealed high levels of Ad[I/PPT-E1A] sequestered in the
cytoplasm of these cells. Adenoviral green fluorescent protein reporter studies showed no evidence for nuclear
localization, suggesting that the cytotoxic effects of Ad[I/PPT-E1A] in human primary hepatocytes are related to
viral sequestration. Also, hepatocytes had increased amounts of coxsackie adenovirus receptor surface protein.
Active viral replication was only observed in the permissive primary prostate cells and LNCaP prostate cell line,
and was not evident in any of the other nonprostate cells types tested, confirming the specificity of Ad[I/PPT-
E1A]. Thus, using a relevant panel of primary human cells provides a convenient and alternative preclinical assay
for examining the specificity of conditionally replicating oncolytic adenoviruses in vivo.
Introduction
The field of gene therapy has rapidly expanded in thelast 20 years, with particular efforts focused on cancer
treatment (Vorberg and Hunt, 2002). Viral vectors remain the
most efficient vehicles for transferring therapeutic genes into
human cells, and various approaches have been employed,
including suicide-gene therapy, oncolytic adenovirus therapy,
immunogene therapy, and vaccine-based strategies. Of the
1,644 gene-therapy clinical protocols reported (see Wiley Web
site: www.wiley.com/legacy/wileychi/genmed/clinical/),
29% use adenovirus vectors or adeno-associated vectors to
deliver therapeutic or marker genes. The human serotype 5
adenovirus is often the vector of choice, because it is able to
transduce cells at high efficiency and independently of cell
division. Oncolytic gene therapy for cancer has evolved from
utilizing replication-defective adenoviruses containing a sin-
gle therapeutic gene, to conditionally replicating oncolytic
adenoviruses (CRAds), which allow preferential replication in
target cancer cells. Such CRAds can produce hundreds of viral
progeny per cell and result in an amplified therapeutic gene-
targeted response as they spread locally, infecting larger
numbers of neighboring cells until all susceptible cells are
eliminated. Thus, infection by a small number of CRAd par-
ticles could theoretically eliminate a large tumor burden.
In humans, both replication-competent and replication-
incompetent adenoviruses have shown low toxicity, with
specific antitumor activity in preclinical tumor models and
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humans (Kim et al., 1994; Freytag et al., 1998, 2002; Rogulski
et al., 2000). Human adenovirus-based vectors are hampered,
however, by the lack of a good animal model in which to
assay off-target effects and to generate high viral titers to
study human adenoviral serotypes ( Jogler et al., 2006). Un-
fortunately, human adenoviruses are at best only semi-
permissive even in nonhuman primates (Maitland et al.,
2010). Animal adenoviruses have been studied in their
corresponding host cells, to allow safety and efficacy issues
to be addressed, but systems for extrapolating such con-
clusions to humans are limited. In 1999, the use of adeno-
virus vectors as a gene-delivery system generated much
controversy when a patient died from the injections of an
ornythine transcarbamylase–encoding adenovirus. The im-
munocompromised patient received the highest dose ever
administered in clinic [3.6 · 1013 virus particles (VP)]. This
was the first reported death resulting as a direct conse-
quence of viral gene therapy (Carmen, 2001). As a conse-
quence, the National Institutes of Health and the U.S. Food
and Drug Administration issued tighter guidelines and
regulations, and new standards were set to improve the
quality and safety of adenoviral clinical trials. Thus, there
is a requirement for the generation of more relevant
and convenient preclinical testing protocols for oncolytic
adenoviruses.
Within the European Union GIANT consortium (http://
www.york.ac.uk/biology/units/cru/giant/welcome.htm),
a prostate-specific CRAd is due to be examined in a phase I
dose-escalating clinical trial in patients with localized pros-
tate cancer (Schenk et al., 2010). Prostate cancer is the most
commonly diagnosed cancer in men aged 65 and over and
the second most common cause of cancer death in men in the
United Kingdom. Treatment of localized disease is possi-
ble by radical prostatectomy, but in 35% of cases micro-
metastases can persist after primary treatment and often
develop into an incurable androgen-insensitive disease
(Djavan et al., 2003). Thus, there is an urgent need for im-
proved localized and systemic treatments that provide long-
lasting effects. The prostate-specific CRAd to be used in the
GIANT clinical trial, Ad[I/PPT-E1A], contains a complex
chimeric promoter (Cheng et al., 2004), which combines
the T-cell receptor c-chain alternate reading frame protein
(TARP) promoter (Cheng et al., 2003), with the prostate-
specific PSA- and PSMA- (prostate-specific membrane anti-
gen) enhancer elements, to drive adenoviral replication in
prostate cells only (Cheng et al., 2006). Ad[I/PPT-E1A] has
the added advantage that it is active in both the presence and
absence of androgens, so this virus should also be suitable
for the treatment of patients with castration-resistant pros-
tate cancer. In both in vitro and animal studies, Ad[I/PPT-
E1A] has specifically demonstrated destruction of prostate
tumor cells, for example, by enhancing the survival of mice
bearing tumors (Cheng et al., 2004, 2006). In the proposed
trial, immunocompetent patients with localized prostate
cancer will be treated by a single intraprostatic injection of
Ad[I/PPT-E1A], ranging from 1 · 1011 to 5· 1012 VP, prior to
radical prostatectomy. According to the International Con-
ference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Oncolytic Viru-
ses (September 17, 2009), the regulatory authorities require
evidence that an oncolytic virus to be tested in a clinical trial
cannot replicate in nontarget cells and cause damage to un-
desired organs and tissues. Thus, they must undergo rigor-
ous testing in preclinical toxicology studies to show relevant
oncolytic efficacy and safety.
As an alternative preclinical approach to animal testing, we
have used human nonprostate primary cells in in vitro cell
culture to test whether Ad[I/PPT-E1A] replication is limited
only to the prostate target cells by assessing the specificity and
sensitivity of Ad[I/PPT-E1A] replication and cytolytic killing
in vitro. The primary cell types were chosen for study, because
the parental organs are either close to the site of adenoviral
administration or should be exposed to the highest percentage
of cardiac output (blood flow) and would likely have in-
creased contact with any circulating Ad[I/PPT-E1A] virus
in vivo in the phase I GIANT human clinical trial. They in-
cluded human vascular endothelial cells, bronchial epithelial
cells, urothelial cells, and hepatocytes. In all cases, no repli-
cation of the retargeted Ad[I/PPT-E1A] virus was seen, de-
spite retention of the ability to attach to and penetrate the
various cell types. We conclude that in vitro preclinical testing
procedures using a relevant panel of human primary cells is a
feasible approach for the preclinical analysis of the efficacy
and specificity of oncolytic adenoviruses, and in this respect
will have significant additional value next to animal models.
Materials and Methods
Maintenance of primary cells and cell lines
LNCaP cells (malignant human prostate adenocarcinoma
cell line derived from a lymph-node metastasis; European
Collection of Animal Cell Cultures, Porton Down, UK) were
cultured in RPMI (Invitrogen, UK) supplemented with 10%
heat-inactivated fetal calf serum (FCS; PAA,UK) and 2mmol/L
L-glutamine (Invitrogen, UK). HEK293 cells (human embryonic
kidney cell line; ATCC, Manassas, VA) were cultured in
Dulbecco’s modified Eagle’s medium (DMEM; GIBCO, UK)
supplemented with 10% heat-inactivated FCS (PAA) and
2mmol/L L-glutamine (Invitrogen). The following human
primary cells were maintained in their associated media: pri-
mary human bronchial epithelial cells (HBEC; TCS/Cellworks,
UK) were cultured in bronchial epithelial cell growth medium
with supplements (TCS/CellWorks, UK); primary human
umbilical vein endothelial cells (HUVEC; Lonza, USA) were
cultured in Endothelial Cell Basal Medium with supplements
(Lonza, USA); primary human urothelial cells (HUC; kindly
donated by Professor J. Southgate, Jack BirchUnit forMolecular
Carcinogenesis, University of York, UK) were cultured in Pri-
maria flasks (BD Biosciences, UK) in keratinocyte serum-free
medium (KSFM; Invitrogen, UK) supplemented with 2mmol/
L L-glutamine, epidermal growth factor (EGF), and bovine
pituitary extract (GIBCO, UK); primary human hepatocytes
(kindly provided by Prof. A. Dhawan and Dr. R. Mitry,
Hepatocyte Biology and TransplantationGroup, King’s College
Hospital, UK) were cultured in Eagle’s minimum essential
medium, supplemented with 10% heat-inactivated FCS,
2mmol/L L-glutamine; primary human prostate cells were
isolated with consent, from thick-needle cores of patient tissue
removed by radical prostatectomy (York District Hospital,
York, UK; Castle Hill Hospital, Hull, UK). Prostate cancer was
confirmed by a uropathologist, by histology of adjacent tissue.
Undifferentiated prostate cells were maintained in complete
KSFM supplemented with EGF (Invitrogen), bovine pituitary
extract (Invitrogen), 2 ng/ml leukemia inhibitory factor (Sigma,
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UK), 2ng/ml stem cell factor (Sigma, UK), 1 ng/ml Gm, and
100ng/ml cholera toxin (Sigma, UK). Irradiated STO cells
(mouse embryonic fibroblasts) were routinely added as feeders.
Differentiated primary prostate cells were cultured in 1:1
DMEM:Ham’s F-12 medium (vol/vol; DMEM Culture Med-
ium, Gibco, UK; Ham’s F-12 Culture Medium, Lonza, UK),
2mmol/L L-glutamine, 10% heat-inactivated FCS, and 10nM
dihydrotestosterone (Innovative Research ofAmerica,USA).All
cell culture was performed without the addition of antibiotics.
Adenoviral samples
Ad[I/PPT-E1A] was manufactured at the GMP Facilities at
the Center for Cell and Gene Therapy at Baylor College of
Medicine (Houston, TX), specifically for the European Union
GIANT project. The virus was supplied at a concentration of
1· 1011 VP/ml in 20mM Tris, pH 8.0, 25mM NaCl, 2.5%
glycerol. As a positive viral control, wild-type adenovirus
(AdWT, serotype 5) was used (sourced from ATCC) (batch no.
001504, purity > 99% in buffer: 20mM Tris, pH 8.0, 25mM
NaCl, 2.5% glycerol). Viral titer was 5.8·1011 VP/ml. As a
negative viral control, a replication-incompetent adenovirus
(AdMock) was used (Carlsson et al., 2003). This virus has an
E1-deleted and E3-deleted replication-deficient adenoviral
vector of serotype 5. It contains no extra transgene and was
produced by recombination of pShuttle and pAdEasy1 (He
et al., 1998). AdMock was sourced from Professor Magnus
Essand (University of Uppsala, Sweden) (batch no. 20090505,
purity 99%, inbuffer: 10mMTris-HCl, pH7.9, 1mMMgCl2, 4%
sucrose). The viral titer was 4.1· 1012 VP/ml. Two replication-
incompetent reporter adenoviruses, AdCMV-gfp and AdI/
PPT-gfp, were also sourced from Professor Essand.
MTS assays
LNCaP and primary cells were seeded in triplicate at
80% confluency in 48-well plates, 500 ll/well cell culture
medium. The following day, cells were infected at room
temperature (RT) for 1–2 hr with gentle agitation with 0, 50,
500, and/or 5,000 multiplicity of infection (MOI) (VP/cell) of
either Ad[I/PPT-E1A] or the AdWT. Virus was prepared in
the appropriate cell culture medium for each primary cell
type assayed. After viral incubation, the virus was removed.
The cells were washed with medium and incubated for up to
14 days, at 37C, 5% CO2. Medium was changed on days 3, 6,
7, 10, and 11. On days 0, 3, 6, 10, and 14, 60ll/well MTS
reagent (CellTiter 96 AQueous One Solution Cell Proliferation
Assay; Promega, UK) was added and incubated for 2 hr at
37C, 5% CO2, followed by ultraviolet irradiation for 15min.
The absorbance at 485 nm and 620 nm was determined for
each sample on a POLARstar OPTIMA plate reader (BMG
Labtech, UK). Average final absorbance values for the tripli-
cate wells were calculated and standard error propagation
determined by using Microscoft Excel (Redmond, WA). The
percent cell viability for each time point was determined by
normalization against MOI 0, plotted with SigmaPlot
(Hounslow, London, UK) and presented as bar graphs.
Adenoviral replication assays using hexon titration
Primary cells and cell lines were seeded at 80% confluency
in 12-well plates. Twenty-four hours later, cells were infected
in triplicate with Ad[I/PPT-E1A] or AdWT at MOI 0 and 500
for 1–2 hr at RT, with gentle agitation. Virus was removed by
washing the cells with culture medium, and subsequently
the cells were incubated at 37C, 5% CO2 for 14 days. Fresh
medium was added every 3 days to maintain cell viability.
Culture media from the cells were collected on days 3, 6, 10,
and 14 post infection and stored at or below - 75C. On days
7 and 11, medium was changed and discarded. Cells were
harvested on day 14 where possible, and total cell lysates
were prepared by repeated freeze/thaw. Hexon titer assays
were performed in triplicate on 2.5 · 105 HEK293 cells
(ATCC) using serially diluted viral-infected medium sam-
ples, following the Adeno-X Rapid Titre Kit procedure
(Clontech, UK). By using this kit, adenoviral plaques were
detected by immunostaining using an anti-hexon antibody
(Clontech, UK), and viral plaques were counted under light
microscopy. Mean viral titers for each time point and cor-
responding standard deviations were calculated with Mi-
crosoft Excel. Bar graphs were plotted in SigmaPlot with
standard errors shown for each sample.
Ad[I/PPT] promoter expression in primary human
hepatocytes using green fluorescent
protein (gfp) reporter adenovirus
Primary prostate and hepatocyte cells were infected with
either AdCMV-gfp or AdI/PPT-gfp virus at MOI 500 for
2 hr. Virus was removed by washing the cells with culture
medium, and the cells were incubated at 37C, 5% CO2 for
48 hr. After this time, gfp fluorescent images were taken at
· 60 magnification, under oil emersion, using a Nikon Eclipse
TE300 fluorescent microscope.
Quantitative PCR (qPCR) analysis of adenoviral
genome replication
Primary hepatocytes were infected in triplicate with Ad-
Mock and AdWT at MOI 500 and with Ad[I/PPT-E1A] at
MOI 5, 50, and 500 for 2 hr at RT. Virus was removed by
washing the cells with culture medium, and the cells were
incubated at 37C, 5% CO2. Cells were harvested at 2, 24, and
48 hr, and genomic DNA was extracted using a DNeasy
Blood and Tissue kit (Qiagen). qPCR was performed on an
ABI Step-One-Plus Real Time PCR machine. Amplification of
an 84-bp fragment of the adenovirus fiber gene was carried
out using the primers 5’ TGGCTGTTAAAGGCAGTTTGG 3’
and 5’ GCACTCCATTTTCGTCAAATCTT 3’ with detection
of amplified sequences by a Taqman probe (5’ TCCAAT
ATCTGGAACAGTTCAAGTGCTCATCT 3’), which was la-
beled at the 5’ end with the FAM fluorophore and at the 3’
end with the TAMRA quencher. Primers and probe were
purchased from Sigma Genosys, UK. Reactions were carried
out in a volume of 20 ll in ABI Taqman Fast Master mix
(Applied Biosystems, UK), containing primers and probe at
concentrations of 1.0 lM and 0.1 lM, respectively. Thermo-
cycling parameters were 2min at 50C, 10min at 95C fol-
lowed by 40 cycles of 95C (30 sec) and 60C (2min).
Analysis of the data was carried out using the software
provided, and test samples were compared to standards of
known viral DNA content. Standard curves were prepared
by spiking serial dilutions of virus into hepatocyte genomic
DNA. Data are presented as bar graphs plotted in SigmaPlot
with standard errors shown for each sample.
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Localization of adenovirus in primary cells
with immunogold labeling of the hexon capsid protein
using transmission electron microscopy (TEM)
Primary cells were seeded in appropriate cell culture
media, onto Thermanox plastic coverslips (NUNC, UK)
coated in a thin layer of Matrigel (Invitrogen). The cells were
infected with MOI 500 of either AdWT, Ad[I/PPT-E1A], or
AdMock for 1 hr. The virus was removed, and the cells were
cultured for a further 36 hr. Cells were then fixed in 2%
glutaraldehyde for 20min. After washing in 100mM sodium
phosphate buffer, adherent cells were osmicated and dehy-
drated in a series of graded alcohols. A final solution of 50%
TAAB resin (TAAB Laboratories Ltd., Australia) and 50%
absolute ethanol was applied with warming to evaporate off
all traces of alcohol. Resin-filled capsules were inverted
over the coverslips and left to polymerize overnight at 60C.
Ultrathin (70 nm) sections were cut and collected on nickel
grids. Adenovirus-infected cells were observed on an FEI
Tecnai G2 transmission electron microscope, operated at
120 kV. Images were captured on an SIS MegaView II
camera.
To localize the hexon capsid protein by immunogold la-
beling of virus particles, primary cells were infected with
Ad[I/PPT-E1A] at MOI 500 for 1 hr at RT. The virus was
removed, and the cells were cultured for a further 60 hr. Cells
were washed in PBS, removed from the well surface using a
cell scraper, and collected in a 1.5-ml Eppendorf tube. Cells
were then fixed and processed for cryosectioning following
the method of Tokuyasu (1986). Immunogold labeling of
infected adenoviruses within the primary cells using a rabbit
polyclonal anti-hexon antibody to adenovirus serotype 5
(catalog no. ab24240; Abcam, UK) was performed following
the procedure of Mitry et al. (2000). Adenovirus within pri-
mary cells was observed on an FEI Tecnai G2 transmission
electron microscope, operated at 120 kV. Images were cap-
tured on an SIS MegaView II camera.
Immunocytochemical detection of coxsackie
adenovirus receptor (CAR) protein in nonprostate
primary cells
CAR (green) was detected in nonprostate primary cells
and prostate cell lines by immunofluorescent staining using a
primary anti-CAR mouse monoclonal antibody (clone RmcB;
Millipore Ltd.) (at 1:50) and a goat anti-mouse Alexa 488
secondary antibody (at 1:500). For cell morphology, actin
(red) was detected using an anti-actin rabbit monoclonal
antibody (clone EP184E; Millipore Ltd.) (at 1:300) and a goat
anti-rabbit Alexa 568 secondary antibody (at 1:500). Cells
were mounted in VECTORSHIELD containing DAPI (Vector
Laboratories, Inc.) to visualize the nuclei (blue). Fluorescent
images were taken at · 60 magnification, under oil, using a
Nikon Eclipse TE300 fluorescent microscope.
Results
Cytotoxicity of Ad[I/PPT-E1A] infection
of human primary cells
Using a colorimetric MTS assay to determine cytotoxicity,
cell viability was measured to determine whether the pros-
tate-specific Ad[I/PPT-E1A] could kill nonprostate primary
cells. The cytotoxicity data for the infection of primary cells
with a positive control adenovirus, AdWT, compared with
the prostate-specific adenovirus, Ad[I/PPT-E1A], are shown
in Fig. 1. AdWT virus was cytotoxic to all primary cells in a
dose- and time-dependent manner, and at all concentrations
tested all cells were dead by the final day (day 14) of the
assay. In two positive control cell types (prostate cells), Ad[I/
PPT-E1A] showed significant cytotoxic effects at MOI 500 and
5,000 in LNCaP cells and in basal primary prostate cells by
day 14 (Fig. 1A and B). This confirmed that the MTS assay
was able to detect cell death caused by Ad[I/PPT-E1A].
There was no significant cytotoxicity associated with
Ad[I/PPT-E1A] infections in bronchial, endothelial, or ur-
othelial cells at any virus concentration (Fig. 1C–E and Table 1).
In primary human hepatocytes, there was no significant cy-
totoxicity associated with Ad[I/PPT-E1A] infections at lower
virus concentration (MOI 50). However, at higher viral
amounts (MOI 500 and 5,000), a large number of dead he-
patocytes were observed at day 6 with Ad[I/PPT-E1A] virus
(Fig. 1F and G and Table 1). One possible mechanism of
action for the cytotoxicity of Ad[I/PPT-E1A] in the fragile
hepatocytes is an excessive virus uptake and overloading
of the cell with virus particles. A replication-incompetent
adenovirus (AdMock) was used to transduce primary he-
patocytes to examine the potential of viral load for initiating
the observed cytotoxic effects (Fig. 1G). These results showed
no cytotoxicity associated with the replication-incompetent
adenovirus, indicating that the cytotoxicity observed in he-
patocytes infected with Ad[I/PPT-E1A] was most likely not
due to nonspecific adenoviral particle overloading. How-
ever, digital images of hepatocytes in culture throughout the
duration of the assay showed that the uninfected cells were
dying by day 6, indicating their fragile nature when main-
tained in prolonged in vitro cell culture conditions (Fig. 2).
The cytotoxicity seen in hepatocytes was further investi-
gated by adenovirus gfp reporter assays, genome-replication
studies, adenoviral replication assays, and TEM studies to
determine whether the Ad[I/PPT-E1A] virus was actively
replicating, or whether this observation was due to another
effect (see below).
Ad[I/PPT-E1A] replication in human primary cells
The replication capacity of Ad[I/PPT-E1A] in vascular
endothelial cells, bronchial epithelial cells, urothelial cells,
and hepatocytes was assessed by determining the presence
of active viral particles secreted into the cell culture media at
various times after viral infection, and in cell lysates at the
final time point of the assay. Primary prostate cells along
with a prostate-derived cell line, LNCaP, were used as pos-
itive cell-type controls for Ad[I/PPT-E1A] replication. The
collected supernatants and cell lysates were titered by in-
fection of HEK293 cells, and the infectious plaques resulting
from active Ad[I/PPT-E1A] virus were detected by im-
munostaining for adenovirus hexon protein (Fig. 3). As a
reference for nonspecific viral replication, wild-type adeno-
virus (AdWT) was included in each assay. The infectivity of
the cell-culture supernatants collected at the different time
points was compared with the level of infectivity of the input
virus (AdWT or Ad[I/PPT-E1A]), namely, the ‘‘infection titer.’’
To define the infection titers, HEK293 cells (2.5· 105) were
directly infected with the same concentrations (in VP/ml) of
AdWT or Ad[I/PPT-E1A] as were used to infect the prostate
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FIG. 1. Cytotoxicity bar graphs for LNCaP cells, human primary basal prostate cells, human primary bronchial epithelial
cells (HBEC), human primary umbilical vein endothelial cells (HUVEC), human primary urothelial cells (HUC), and human
primary hepatocytes infected with Ad[I/PPT-E1A] or AdWT at MOI 0, 50, 500, and 5,000, and human primary hepatocytes
treated with Ad[I/PPT-E1A], AdWT, or AdMock at MOI 0, 5, 50, and 500. MTS assays were performed on cells at days 0, 3, 6,
10, and 14 where possible. Viability is expressed as a percentage of untreated cells (MOI 0), and the means – SD are shown for
triplicate wells.
Table 1. Viability of Human Nonprostate Primary Cells After Treatment with Ad[I/PPT-E1A] and AdWT
AdWT (MOI 500) Ad[I/PPT-E1A] (MOI 500)
Human cell type % cell viability Cytotoxic % cell viability Cytotoxic
Bronchial epithelial cells 1 – 1 Yes 96 – 24 No
Umbilical vein endothelial cells 3 – 0 Yes 107 – 8 No
Urothelial cells 21 – 2 Yes 104 – 9 No
Hepatocytes - 1 – 1 Yes 20 – 3 Yes
Viability at day 6 for human primary urothelial cells, at day 10 for human primary umbilical vein endothelial cells and human primary
hepatocytes, and at day 14 for human primary bronchial epithelial cells after treatment with Ad[I/PPT-E1A] or AdWT at MOI 500 is
expressed as a percentage of untreated cells (MOI 0). The means– SD are shown for triplicate wells.
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cancer cell line and human primary cells. These concentrations
differed between the various cell types (see Table 2). In cases
where the data showed viral titers above the infection titer, we
concluded that the virus was actively replicating in these cells
(Fig. 3A–C). Viral titers below the infection titer suggested that
the virus had been sequestered internally, and active viral
replication was not occurring. Throughout the duration of the
assay, cells undergoing apoptosis released their sequestered
virus into the medium, which was observed in titers at day 6,
10, and 14 in bronchial epithelial cells, urothelial cells, and
hepatocytes (Fig. 3D, F, and G).
To establish the sensitivity and time parameters for the
assay, infections of permissive LNCaP cells with AdWT and
Ad[I/PPT-E1A] were carried out (Fig. 3A). The data revealed
that both AdWT and Ad[I/PPT-E1A] actively replicated in
LNCaP cells. The replication level titers were 10-fold less for
Ad[I/PPT-E1A], and there was also a slight delay compared
with the AdWT virus (Fig. 3A). Similar replication assays
were carried out with cultures from primary prostate tissue,
both undifferentiated (basal cells) and cultures induced to
differentiate to a luminal phenotype, both at MOI 500 (VP/
cell). This MOI value was chosen to eliminate even inefficient
attachment and replication as a possibility in vivo, although
such viral titers would be impossible to achieve except in
close proximity to the needle-injection site. We observed
active replication of Ad[I/PPT-E1A] in basal prostate epi-
thelial cells, increasing to > 3.13 · 107 infectious units (ifu)/
ml by day 14 (ifu > 795% of the viral load) compared with a
peak titer of 6.72 · 106 ifu/ml at day 14 in differentiated
prostate epithelia (ifu 172% of the viral load) (Fig. 3B and C).
Furthermore, the rate of replication of Ad[I/PPT-E1A] in
differentiated prostate epithelial cells was much slower than
that in both LNCaP cells and basal prostate epithelial cells,
suggesting that viral replication in these cells is attenuated.
In the cases of bronchial, endothelial, and urothelial cells,
there was no detectable replication of Ad[I/PPT-E1A] when
compared with the input infection titers (Fig. 3D–F). How-
ever, there was evidence of sequestered viral release
throughout the different time points of the assay, as the cells
naturally died in culture. In contrast, efficient replication of
AdWT was observed in these cell types.
We examined four independent donor primary hepato-
cyte samples, all of which showed high levels of AdWT
replication. Although significant amounts of Ad[I/PPT-E1A]
were retained by the cells, no net viral increase was ob-
served, suggesting that Ad[I/PPT-E1A] does not replicate in
hepatocytes (Fig. 3G). The data indicated that hepatocytes
can ingest both AdWT and Ad[I/PPT-E1A]. Table 3 sum-
marizes viral yields per cell for each cell type studied, as well
as the maximum percentage viral load. When compared with
active replication in primary prostate samples and LNCaP
cells, the replication data for Ad[I/PPT-E1A] indicate a
greatly reduced number of virus particles per cell in the
nonprostate primary cells, including hepatocytes, after in-
fection with the high MOI 500, indicating the presence of
residual, nonreplicating virus.
FIG. 2. Digital images of cultures of uninfected primary hepatocytes (no virus) and hepatocytes infected with AdWT or
Ad[I/PPT-E1A] at MOI 500. Images were taken on days 3, 6, and 10 post infection. · 10 and · 20 refer to the microscope
magnification of the images.
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FIG. 3. Viral replication bar
graphs for LNCaP cells,
human primary basal pros-
tate cells, human primary
differentiated prostate cells,
human primary bronchial
epithelial cells (HBEC), hu-
man primary umbilical vein
endothelial cells (HUVEC),
human primary urothelial
cells (HUC), and human
primary hepatocytes infected
with Ad[I/PPT-E1A] and
AdWT at MOI 500. Infected
culture media collected on
days 3, 6, 10, and 14 (where
possible) were titered in
hexon titer assays, and the
means – SD are shown for
triplicate wells. The lines
indicate the input load of
infectious virus: solid line,
AdWT; dashed line, Ad[I/
PPT-E1A]. Black bars, AdWT
virus; gray bars, Ad[I/PPT-
E1A] virus. *Viral titer is
greater than maximum titer
measured in the hexon titra-
tion assay, i.e., > 3.13 · 107
ifu/ml or > 1.1 · 109 ifu/ml.
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I/PPT transcriptional activity in primary
hepatocytes and prostate cells
To establish the possibility of active Ad[I/PPT-E1A] rep-
lication in primary hepatocytes, we examined I/PPT pro-
moter activity in both primary hepatocytes and primary
prostate cells using serotype 5 adenoviruses that express gfp.
The primary cells were infected for 48 hr with MOI 500 AdI/
PPT-gfp or AdCMV-gfp. Figure 4 shows gfp expression from
AdI/PPT-gfp virus in prostate cells, but not in hepatocytes,
whereas the control AdCMV-gfp virus expressed gfp in both
cell types after this time.
Ad[I/PPT-E1A] genome replication in hepatocytes
qPCR studies were performed in primary hepatocytes to
monitor any increase in adenoviral genome content between
2 and 48hr post infection (Fig. 5). Hepatocyte cultures were
infected in triplicate with AdMock or AdWT at MOI 500 and
with Ad[I/PPT-E1A] at MOI 5, 50, and 500. Genomic DNA
was extracted from the cells at 2, 24, and 48hr, and adeno-
viral genome quantities were analyzed by qPCR targeting an
84-bp fragment of the adenoviral fiber gene. At 48hr, at MOI
values under 500, which are not associated with a cytotoxic
effect in hepatocytes, Ad[I/PPT-E1A] genome-replication
levels were equivalent to those of the replication-incompetent
AdMock, i.e., 1.21· 10–3 ng compared with 1.36· 10–3 ng for
MOI 5, respectively. This level was 3,600 times lower than
levels with AdWT and comparable to the hepatocyte hexon
titer replication data. However, at the much higher MOI 500,
although the Ad[I/PPT-E1A] genomic DNA quantity had
increased, it was still significantly lower (45 times) than that
of the AdWT control. The data suggest that at extreme MOI
values at or above 500, Ad[I/PPT-E1A] genomic DNA rep-
lication occurs, but as the replication assays do not show
active viral particle production even at MOI 500, it is unlikely
that these genomes are packaged into infective viral particles
that could actively establish secondary infections. TEM
studies were performed to examine this finding further.
Intracellular localization of Ad[I/PPT-E1A] particles
in human primary hepatocytes by TEM
and immunogold TEM
We examined the location of adenovirus particles in in-
fected basal prostate cells and hepatocytes initially by TEM.
TEM images showed replicated AdWT in ‘‘rafts’’ within the
nuclei of both primary prostate cells and primary hepato-
cytes by 60 hr post infection (Fig. 6A and C). We also ob-
served replicated Ad[I/PPT-E1A] in similar rafts in the
nuclei of primary prostate cells (Fig. 6B). Replication rafts
were not observed in the nuclei of primary hepatocytes with
Table 2. Viral Titer Counts for the Input Virus and the Infection Titers of the Prostate
LNCaP Cell Line and the Human Nonprostate Primary Cell Types
Human
cell types
Number
of cells plated
per well MOI
AdWT
input virus
(VP/ml)
AdWT infection
titer counts
(ifu/ml)
Ad[I/PPT-E1A]
input virus
(VP/ml)
Ad[I/PPT-E1A]
infection titer
counts (ifu/ml)
LNCaP cells 240,000 500 6.0 · 107 1.4 · 107 6.0 · 107 5.6 · 106
Undifferentiated prostate cells 70,000 500 3.5 · 107 4.4 · 106 3.5 · 107 3.9 · 106
Differentiated prostate cells 140,000 500 7.0 · 107 4.8 · 106 7.0 · 107 3.3 · 106
Bronchial epithelial cells 70,000 500 3.5 · 107 4.4 · 106 3.5 · 107 3.9 · 106
Umbilical vein endothelial cells 70,000 500 3.0 · 107 4.3 · 106 3.0 · 107 3.1 · 106
Urothelial cells 60,000 500 2.5 · 107 3.6 · 106 2.5 · 107 2.6 · 106
Hepatocytes 800,000 500 4.0 · 108 1.1 · 108 4.0 · 108 4.0 · 107
Human primary cell and LNCaP cell input viral titer counts (in VP/ml) and directly assayed active viral infection titers (in ifu/ml) were
measured by hexon titer assays for AdWT and Ad[I/PPT-E1A]. The mean values are shown for triplicate wells.
Table 3. Viral Replication Status for Ad[I/PPT-E1A] and AdWT in the LNCaP
Cell Line and in the Human Nonprostate Primary Cell Types
AdWT (MOI 500) Ad[I/PPT-E1A] (MOI 500)
Human cell type
Peak virus
titer
(ifu/ml)
ifu per cell
(ifu as %
of input)a
Viral
replication
status
Peak virus
titer
(ifu/ml)
ifu per cell
(ifu as %
of input)a
Viral
replication
status
LNCaP 1.6 · 109 7.5 · 103 (13,333) Active 7.3 · 107 304 (1,304) Active
Undifferentiated
(basal prostate)
> 3.1 · 107 > 443 ( > 705) Active > 3.1 · 107 > 443 ( > 795) Active
Differentiated prostate 1.1 · 109 7.9 · 103 (22,917) Active 6.7 · 106 48 (203) Attenuated
Bronchial epithelial > 3.1 · 107 > 443 ( > 721) Active 4.5 · 104 0.64 (1.15) Residual
Umbilical vein endothelial > 3.1 · 107 > 517 ( > 721) Active 8.5 · 103 0.14 (0.27) Residual
Urothelial > 3.1 · 107 > 620 ( > 861) Active 9.4 · 104 1.88 (3.62) Residual
Hepatocytes 2.8 · 108 3.5 · 103 (255) Active 1.9 · 104 0.22 (0.05) Residual
Replication status of AdWT and Ad[I/PPT-E1A] in the primary cell types and LNCaP cell line is shown with the peak viral titers, the
number of infectious viral particles per cell, and the active virus represented as a percentage of the input virus load.
aThe number of infectious units (ifu) per cell calculated by dividing the peak viral titer by the number of cells available for infection at day 0.
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either Ad[I/PPT-E1A] or AdMock virus. However, there
were large numbers of Ad[I/PPT-E1A] and AdMock virus
particles sequestered, only in the hepatocyte cytoplasm, in-
dicating no evidence for viral replication in these cells. (Fig.
6D and E). To validate that the particles observed within the
cell cytoplasm, as well as the raft formations in the nuclei,
were adenovirus, we performed immunogold labeling of the
hexon protein located in the viral capsid, using a rabbit
polyclonal antibody linked to immunogold nanoparticles. In
primary prostate cells, the virus particles situated in the
nuclear rafts colocalized with the hexon immunogold nano-
particles (Fig. 6F and G).
CAR levels in nonprostate primary cells
Finally, the protein levels of the primary adenovirus re-
ceptor CAR (green) were measured by immunocytochemistry
in primary nonprostate bronchial epithelial cells (HBEC),
vascular endothelial cells (HUVEC), and hepatocytes and
compared with those of the prostate cell line LNCaP and the
adenoviral replication-competent HEK293 cells. Figure 7 con-
firms that CAR is expressed at high levels in HEK293 cells and
LNCaP cells, particularly at lateral cell junctions where it co-
localizes (yellow) with actin (red). In contrast, very little CAR
was detected in the bronchial epithelial cells and vascular
endothelial cells. Interestingly, higher CAR levels were seen in
the cytoplasm and at the cell surface of primary hepatocytes,
suggesting a possible route of viral entry into these cells.
Discussion
We have applied in vitro cell culture techniques as a pre-
clinical testing approach to examine the ability of Ad[I/PPT-
EA], a human prostate-specific conditionally replicating
adenovirus, to infect, replicate, and produce cytotoxic effects
in nonprostate primary cells from humans. Initially, we ex-
amined the cytotoxic effects of Ad[I/PPT-E1A] at a range of
MOI values in primary bronchial epithelial cells, urothelial
cells, vascular endothelial cells, and hepatocytes using an
MTS assay. We compared these data with viral cytotoxicity
in two permissive cell types: the LNCaP prostate cell line and
primary prostate cells isolated from a prostate cancer patient.
The data revealed high levels of cytotoxicity of Ad[I/PPT-
E1A] in both prostate cell types studied, and confirmed that
no significant cytotoxic effects were observed in all the
nonprostate cells, apart from the human hepatocytes (Fig.
FIG. 5. Adenoviral genome replication bar graph for
human hepatocytes, measured by qPCR. Hepatocyte cells
were infected in triplicate with AdMock or AdWT at MOI
500 and with Ad[I/PPT-E1A] at MOI 5, 50, and 500. Cells
were harvested at 2, 24, and 48 hr, and qPCR to detect viral
DNA quantities was performed using a probe/primer mix
targeted to an 84-bp fragment of the adenovirus fiber gene.
The means – SEM are shown for triplicate wells.
FIG. 4. Fluorescent images
showing I/PPT-specific pro-
moter activity in primary
human prostate cells, but not
in human hepatocytes, 48 hr
after infection with MOI 500
AdCMV-gfp virus or Ad[I/
PPT]-gfp virus. Images were
taken at · 60 magnification
under oil.
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1F). This effect could not be explained by active replication of
Ad[I/PPT-E1A] virus particles, leading to viral burst and
subsequent death of infected hepatocytes, because replica-
tion was not detected in these cells using the hexon im-
munostaining assay, which stains for the capsid protein (see
below). Equally, I/PPT promoter activity was not observed
in primary hepatocytes infected with an AdI/PPT-gfp virus
(Fig. 4). In contrast, AdWT induced cytotoxicity of human
primary hepatocytes even at MOI 5 (Fig. 1G), implying at
least 100-fold higher activity toward these cells compared
with Ad[I/PPT-E1A]. Furthermore, AdWT was confirmed to
replicate in primary hepatocytes.
Viral replication assays were carried out to examine the
replication activity of Ad[I/PPT-E1A] in the nonprostate
primary cell types. By infecting the primary cells with Ad[I/
PPT-E1A] at MOI 500 and titering the medium samples
collected at different time points by hexon titer assays, the
data clearly showed that Ad[I/PPT-E1A] did not actively
replicate in any of the nonprostate primary cell types stud-
ied, including hepatocytes. In contrast, highly active repli-
cation was observed in the positive control cells, i.e., the
LNCaP prostate cell line and the primary prostate cells. In-
terestingly, primary prostate cells induced to terminally
differentiate and form cellular multilayers in the presence of
FIG. 6. TEM images of
human primary prostate cells
(A, B) and hepatocytes (C, D,
E) 60 hr post infection with
500 MOI AdWT virus (A, C),
Ad[I/PPT-E1A] virus (B, D),
and AdMock virus (E). The
following labels are used in
the images: C, cytoplasm; ER,
endoplasmic reticulum; M,
mitochondria; N, nucleus; nm,
nuclear membrane; Nu, nu-
cleolus. Virus particles (ar-
rows) are observed in both cell
cytoplasm and nucleus. (F)
Ad[I/PPT-E1A] virus is local-
ized in primary prostate cells
using immunogold labeling of
the hexon protein in the viral
capsid (primary hexon anti-
body used at 1:100; secondary
immunogold antibody at
1:20). Virus particles are often
located in viral replication
‘‘rafts’’ that colocalize with
immunogold labeling of the
hexon protein. (G) Absence of
hexon immunogold labeling
associated with Ad[I/PPT-
E1A] virus particles when the
primary hexon antibody is
omitted. Immunogold parti-
cles are indicated by ‘‘ > .’’
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serum and 10nM dihydrotestosterone showed delayed viral
replication with Ad[I/PPT-E1A], indicative of attenuated
viral replication. This may be because superficial differenti-
ated luminal-like cells can mask the CAR located on the
underlying basal cell surface, which is required for adeno-
viral infection. Evidence for a reduction in CAR expression in
differentiated primary prostate tissue has been previously
reported by IF studies (Maitland et al., 2010). This was not
observed for the AdWT virus; however, at high viral titers,
AdWT may also transduce cells via other surface receptors
and by endocytosis mechanisms (Carlisle et al., 2009).
The transcriptional activity of the prostate-specific I/PPT
promoter was examined in primary hepatocytes using a gfp-
reporter adenovirus (Fig. 4). After 48 hr, no evident gfp ex-
pression was observed in hepatocytes infected with MOI 500
AdI/PPT-gfp. However, the I/PPT promoter was transcrip-
tionally active in primary prostate cells by this time.
To examine this further, we used a highly sensitive qPCR
assay to quantify Ad[I/PPT-E1A] genome replication in he-
patocytes at MOI 5, 50, and 500 and compared the levels with
those of AdMock and AdWT at MOI 500. At MOI < 500, the
quantity of Ad[I/PPT-E1A] genomic DNA was comparable
to that of the replication-incompetent AdMock. Only at the
highest MOI used (MOI 500), was there an increase in ge-
nome quantity, indicative of genome replication. This may
be due to ‘‘leaky’’ TARP promoter activity within the ade-
novirus genome. In this context, the TARP promoter is sur-
rounded by less condensed chromatin compared with the
human genome context (on chromosome 7), where highly
condensed chromatin tightly regulates TARP gene expres-
sion. However, the hepatocyte replication data indicated
that active viral replication due to viral burst, cell death,
and reinfection was not occurring in these cells, suggesting
that these genomes were not packaged into infective, rep-
lication-competent adenovirus. Electron microscopy images
were taken of AdWT-, AdMock-, and Ad[I/PPT-E1A]-
infected prostate cells and human hepatocytes. The data
confirmed the hypothesis that Ad[I/PPT-E1A] virus did not
actively replicate in hepatocytes, but was sequestered in
large numbers in the cell cytoplasm and was not present
in the nucleus. This observation was confirmed with the
replication-incompetent virus, which was also present in
high numbers in the hepatocyte cytoplasm. In contrast,
AdWT was organized in rafts in the nuclei of both primary
prostate cells and primary hepatocytes, which is indicative
of replication.
Taking the above observations into consideration, the
replication data (Fig. 3) for hexon immunostaining, the
adenoviral-gfp reporter assay, and the outcome of the elec-
tron microscopy analyses, all indicate that Ad[I/PPT-E1A]
does not actively replicate in human primary hepatocytes.
The cytotoxic effect observed in these cells upon treatment
with Ad[I/PPT-E1A] (Fig. 1F and G) might be explained by
cytoplasmic sequestration of viral particles in combination
with a fragile condition and short life span of human pri-
mary hepatocytes in in vitro culture (Fig. 2). The increased
CAR levels observed in the hepatocyte cytoplasm and on the
surface membranes (Fig. 7), when compared with bronchial
epithelial cells and vascular endothelial cells, could clearly
result in higher levels of adenovirus being sequestered
within the hepatocyte cytoplasm.
It is well known that culture conditions, including seeding
density, matrix conditions, and medium supplements, affect
the morphological development, expression of metabolic
enzymes, response to drugs, and survival of cultured human
primary hepatocytes. To the best of our knowledge, the effect
of oncolytic adenoviruses on cultured human primary he-
patocytes has not been reported. Therefore, it remains to be
clarified whether this phenomenon is an artifact of the model
system used. When an extrapolation of the in vitro conditions
in which cytotoxicity in cultured human primary hepato-
cytes, as observed here, is made to the in vivo situation, and
assuming a worst case scenario of maximal viral progeny
generation within the prostate, substantial leakage of virus
from the prostate into the circulation, and lack of any neu-
tralization of systemic virus in the circulation, it is clear that
the in vitro upper safety margin threshold (MOI 50) will
never be achieved in a liver of a patient treated locally with
Ad[I/PPT-E1A] in the planned clinical trial. It has to be taken
FIG. 7. Immunocytochemical detection of CAR protein
(green) in HEK293 cells, LNCaP cells, primary human
bronchial cells (HBEC), primary human umbilical vein en-
dothelial cells (HUVEC), and human hepatocytes. Actin (red)
stained for cell morphology, and DAPI (blue) was used to
visualize the nuclei. Images were taken at · 60 magnifica-
tion, under oil.
PRECLINICAL TESTING OF HUMAN ADENOVIRUS 11
into account that the human body is capable of efficient
neutralization of systemic adenovirus by binding to eryth-
rocytes via the complement receptor CR1 and CAR ex-
pressed on the surface of these cells (Carlisle et al., 2009) and
by the immune system. These neutralization effects are the
most likely explanation for the fact that systemic adenovirus
infection in immunocompetent individuals, such as the pa-
tients to be recruited in the planned trial, is not associated
with serious effects, and that to date, oncolytic adenoviruses
have been well tolerated by patients even upon systemic
administration. For example, intravenous administration of
CG7870, a PSA-selective oncolytic adenovirus expressing the
E3 region proteins that are involved in controlling the host
immune response, was well tolerated up to 6.0 · 1012 VP in
patients with hormone-refractory prostate cancer (Small
et al., 2006). In addition, only 20% of the patients with met-
astatic colorectal cancer treated with up to eight infusions in
the hepatic artery from 2.0 · 108 to 2.0 · 1012 VP of Onyx-015
experienced transient grade I/II hepatic toxicity (Au et al.,
2007). Finally, mild and transient dose-dependent transami-
nitis was observed after repeated intravenous injections with
Onyx-015 at doses of 2.0 · 1012 VP and higher in 10 patients
with metastatic solid tumors (Nemunaitis et al., 2001). The
systemic levels in these three trials are comparable to the
levels that will be locally administered in our trial (1.0 · 1011
to 5.0 · 1012 VP). Thus, if a part of the locally administered
Ad[I/PPT-E1A] does leak into the circulation, no adverse
effects are to be expected. Based on results from previous
prostate cancer trials on oncolytic adenoviruses, leakage of
Ad[I/PPT-E1A] to the circulation upon intraprostatic ad-
ministration is expected to be minimal. DeWeese et al. (2001)
showed by qPCR that after a single intraprostatic treatment
at 20–80 deposits up to 1.0 · 1013 VP with the prostate-
specific oncolytic adenovirus CV706, 0.007–0.129% of the
administered dose could be detected in blood after 30min in
the majority of the patients. This was followed by a second
viral DNA peak in 13 out of 16 patients between days 2 and
8. In four patients, this peak was higher than the first peak
with the highest peak at < 2% of dose. It was not reported if
the PCR signal was derived from viable virus. In the trials
conducted by Freytag et al. (2002, 2003), using a single in-
traprostatic injection up to 1.0 · 1012 VP with the non-
prostate-specific oncolytic adenovirus Ad5-CD/TKrep, viral
DNA was found in blood up to day 76, but infectious virus
could not be demonstrated.
To reduce hepatotoxicity further, the use of microRNA-
regulated gene expression systems to enhance the safety
and efficacy of viral gene-therapy approaches has been de-
scribed (Sakurai et al., 2011). By inserting four copies of the
hepatocyte-specific microRNA, mir122, into the 3’ untrans-
lated region of the adenoviral E1A transcription cassette,
Cawood et al. (2011) were able to genetically reduce hepatic
adenovirus replication and liver pathology. If required, such
an approach could be applied to further enhance Ad[I/PPT-
E1A] in future clinical trials.
The data presented here confirm the specificity of Ad[I/
PPT-E1A] and are part of the clinical dossier submitted for
regulatory approval. The risk of adverse events in patients
treated with Ad[I/PPT-E1A] related to the in vitro observa-
tion of cytotoxicity of cultured human primary hepatocytes
by clinically unrealistically high amounts of Ad[I/PPT-E1A]
is minimal and will be controlled by recruiting only immu-
nocompetent patients. As a prelude to clinical trials, the use
of multiple primary cultures from a variety of normal human
cell types should provide a convenient assay for testing on-
colytic adenovirus specificity in vivo, to limit and predict any
undesired off-target effects.
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